Multiple Copies of microRNA Binding Sites in Long 3'UTR Variants Regulate Axonal Translation

Cells. 2023 Jan 6;12(2):233. doi: 10.3390/cells12020233.

Abstract

Rapid responses to changes within subcellular compartments of highly polarized cells, such as neuron axons, depend on local translation and post-transcriptional regulation. The mechanism by which microRNAs (miRNAs) regulate this process is not fully understood. Here, using live cell imaging and RNA sequencing analysis, we demonstrated how miRNAs can differentially control hundreds of transcripts at the subcellular level. We demonstrated that the seed match length of the miRNA target-sequence regulates both mRNA stability and protein translation rates. While longer seed matches have an increased inhibitory effect, transcriptome analysis did not reveal differences in seed match length between axonal and somata mRNAs of motor neurons. However, mRNA variants with longer 3'UTR are enriched in axons and contain multiple repeats of specific miRNA target sequences. Finally, we demonstrated that the long 3'UTR mRNA variant of the motor protein Kif5b is enriched explicitly in motor neuron axons and contains multiple sequence repeats for binding miR-129-5p. This subsequently results in the differential post-transcriptional regulation of kif5b and its synthesis in axons. Thus, we suggest that the number of miRNA binding sites at the 3'UTR of the mRNA, rather than the miRNA seed match length, regulates the axonal transcriptome.

Keywords: 3′UTR; KIF5B; RNA localization; RNA translation; axons; miR-129-5p; seed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3' Untranslated Regions / genetics
  • Axons / metabolism
  • Binding Sites
  • Carrier Proteins / metabolism
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism

Substances

  • 3' Untranslated Regions
  • MicroRNAs
  • Carrier Proteins
  • RNA, Messenger

Grants and funding

The Perlson laboratory is supported by the HFSP, Ministry of health, State of Israel—JPND program, Israel Science Foundation (ISF), grant numbers: RGP0026/2020-102, 3-17160, 735/19 respectively, and by the Radala Foundation for ALS research, and Ministry of Science and Technology, State of Israel. Luba Farberov was partially supported by the Kirschman Dvora Eleonora Fund for Parkinson’s Disease studies. Guy Shapira was partially supported by the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University. The Shomron Laboratory is supported by Tel Aviv University Center for Combating Pandemics (TCCP); Horizon 2020—Research and Innovation Framework Programme, PSY-PGx; The Edmond J. Safra Center for Bioinformatics at Tel Aviv University; The Koret-UC Berkeley-Tel Aviv University Initiative in Computational Biology and Bioinformatics; The QBI/UCSF-Tel Aviv University joint Initiative in Computational Biology and Drug Discovery; Israeli Ministry of Defense, Office of Assistant Minister of Defense for Chemical, Biological, Radiological and Nuclear (CBRN) Defense; Foundation Fighting Blindness; Collaborative clinical Bioinformatics research of the Edmond J. Safra Center for Bioinformatics and Faculty of Medicine at Tel Aviv University; Israeli Ministry of Science and Technology, Israeli–Russia; Kodesz Institute for Technologies in Healthcare; Tel Aviv University Healthy Longevity Research Center; Djerassi-Elias Institute of Oncology; Canada-Montreal Friends of Tel Aviv University; Donations from Harold H. Marcus, Amy Friedkin, Natalio Garber, Tal Zohar; Kirschman Dvora Eleonora Fund for Parkinson’s Disease; Joint funding between Tel Aviv University and Yonsei University; Tel Aviv University Innovation Laboratories (TILabs).